Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 84 articles: HTML format

Single Articles

August 2026
1. HU J, Lai C, Xiao Y, Yan Z, et al
   Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.
   Oncogene. 2026 Aug 3. doi: 10.1038/s41388-026-03946.
   PubMed     Abstract available
   
   
   July 2026
2. GAO Y, Liu Y, Ye X, Liu A, et al
   Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer.
   Oncogene. 2026 Jul 29. doi: 10.1038/s41388-026-03900.
   PubMed     Abstract available
   
   
   
3. ZAALBERG A, Lacoste A, Minnee E, Mayayo-Peralta I, et al
   A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
   Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03912.
   PubMed     Abstract available
   
   
   
4. WANG KJ, Wang KY, Chen SX, Ma YT, et al
   RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1.
   Oncogene. 2026 Jul 24. doi: 10.1038/s41388-026-03906.
   PubMed     Abstract available
   
   
   
5. YANG R, Ge Q, Wu F, Long M, et al
   METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.
   Oncogene. 2026 Jul 13. doi: 10.1038/s41388-026-03867.
   PubMed     Abstract available
   
   
   
6. CONG H, Seilani F, Goettl R, He D, et al
   SETDB1-mediated repression of RhoB promotes EMT and metastatic progression in prostate cancer.
   Oncogene. 2026 Jul 8. doi: 10.1038/s41388-026-03893.
   PubMed     Abstract available
   
   
   
7. LIAO Y, Sun W, Li Y, Deng Y, et al
   The RPS15-DDX21 complex drives prostate malignancy through transcriptional activation of SCD1.
   Oncogene. 2026;45:2405-2418.
   PubMed     Abstract available
   
   
   June 2026
8. HODGSON K, Orozco-Moreno M, Peng Z, Blencoe L, et al
   The glycobiology of prostate cancer: an update.
   Oncogene. 2026 Jun 18. doi: 10.1038/s41388-026-03858.
   PubMed     Abstract available
   
   
   
9. GASPAR LOPES J, Markovic A, Champy CM, Aubourg N, et al
   CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer.
   Oncogene. 2026 Jun 9. doi: 10.1038/s41388-026-03842.
   PubMed     Abstract available
   
   
   
10. YANG M, Chen Y, Lai S, Liang X, et al
    MCCC2 stabilizes LTBP1 via suppressing SMURF1-dependent ubiquitination to drive bone metastasis in prostate cancer.
    Oncogene. 2026 Jun 6. doi: 10.1038/s41388-026-03843.
    PubMed     Abstract available
    
    
    
11. CHENG B, Gong L, Xu H, Wang Z, et al
    The microbiome across the prostate disease continuum: from health and BPH to prostatitis/CPPS and cancer.
    Oncogene. 2026;45:1955-1969.
    PubMed     Abstract available
    
    
    May 2026
12. LI S, Kang Y, Guan Y, Li J, et al
    Specifically targeted engineered exosomes loaded with circAKR1A1 enhance tumorigenesis and metastasis in prostate cancer by activating the PI3K/Akt signalling pathway.
    Oncogene. 2026 May 30. doi: 10.1038/s41388-026-03833.
    PubMed     Abstract available
    
    
    
13. LUO M, Wu C, Zhou M, Liu R, et al
    Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1.
    Oncogene. 2026 May 30. doi: 10.1038/s41388-026-03828.
    PubMed     Abstract available
    
    
    
14. ZHANG H, Liu TT, Wu F, Colah AN, et al
    Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer.
    Oncogene. 2026 May 4. doi: 10.1038/s41388-026-03777.
    PubMed     Abstract available
    
    
    April 2026
15. SUN G, Chen S, Chen M, Xiao X, et al
    NSUN2/ALYREF-mediated RNA m5c modification promotes anoikis resistance of prostate cancer through activating autophagy.
    Oncogene. 2026 Apr 7. doi: 10.1038/s41388-026-03762.
    PubMed     Abstract available
    
    
    
16. WEI X, Li X, Pan Y, Zhang Y, et al
    LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer.
    Oncogene. 2026 Apr 1. doi: 10.1038/s41388-026-03737.
    PubMed     Abstract available
    
    
    March 2026
17. LI N, Zoubeidi A, Beraldi E, Gleave ME, et al
    Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.
    Oncogene. 2026 Mar 30. doi: 10.1038/s41388-026-03770.
    PubMed    
    
    
    
18. CHEN CH, Brown R, Vander Griend DJ, Gao AC, et al
    Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.
    Oncogene. 2026 Mar 23. doi: 10.1038/s41388-026-03723.
    PubMed     Abstract available
    
    
    
19. GUCHHAIT K, Yoon HS, An HS, Shin S, et al
    Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD).
    Oncogene. 2026 Mar 9. doi: 10.1038/s41388-026-03717.
    PubMed     Abstract available
    
    
    February 2026
20. LI H, Song Y, Cong Y, Wang C, et al
    YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis.
    Oncogene. 2026 Feb 18. doi: 10.1038/s41388-026-03696.
    PubMed     Abstract available
    
    
    
21. BROOKE GN, Leach DA, Culley RL, Azadova A, et al
    Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.
    Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03682.
    PubMed     Abstract available
    
    
    January 2026
22. XIE W, Chu Q, Brea L, Zeng G, et al
    EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.
    Oncogene. 2026 Jan 7. doi: 10.1038/s41388-025-03662.
    PubMed     Abstract available
    
    
    November 2025
23. LI Y, Zhou Z, Zhang Y, Jia D, et al
    Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer.
    Oncogene. 2025 Nov 24. doi: 10.1038/s41388-025-03631.
    PubMed     Abstract available
    
    
    
24. NEPALI PR, Gonzalez-Kozlova E, Anegondi M, Dogra N, et al
    Effect of TGF-beta mediated phenotypic changes on prostate cancer cell anoikis response.
    Oncogene. 2025 Nov 22. doi: 10.1038/s41388-025-03600.
    PubMed     Abstract available
    
    
    
25. CHEN J, Wang ME, Bawcom AR, Lu Y, et al
    Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation.
    Oncogene. 2025;44:4405-4412.
    PubMed     Abstract available
    
    
    October 2025
26. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2025 Oct 28. doi: 10.1038/s41388-025-03614.
    PubMed    
    
    
    September 2025
27. SHENG H, Shi G, Lu Y, Zheng S, et al
    KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer.
    Oncogene. 2025 Sep 23. doi: 10.1038/s41388-025-03576.
    PubMed     Abstract available
    
    
    
28. GE Y, Han P, Sun Y, Chen Y, et al
    Aging-associated ZNF573 methylation regulates RNF19B-PIK3CA ubiquitination to promote prostate cancer.
    Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03579.
    PubMed     Abstract available
    
    
    
29. CHUKHU M, Dahiya UR, Heemers HV
    Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03573.
    PubMed     Abstract available
    
    
    
30. RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al
    ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
    Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
    PubMed     Abstract available
    
    
    
31. CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al
    Integrated control of cancer stemness by sigma(1) receptor in advanced prostate cancer.
    Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
    PubMed     Abstract available
    
    
    August 2025
32. TONG T, Lei H, Huang M, Yang Z, et al
    HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03548.
    PubMed     Abstract available
    
    
    
33. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03531.
    PubMed    
    
    
    
34. HAO JL, He JQ, Hu H, Zhu ZH, et al
    TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity.
    Oncogene. 2025 Aug 4. doi: 10.1038/s41388-025-03517.
    PubMed     Abstract available
    
    
    
35. SANCHIS P, Sabater A, Lechuga J, Rada J, et al
    PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression.
    Oncogene. 2025 Aug 2. doi: 10.1038/s41388-025-03511.
    PubMed     Abstract available
    
    
    July 2025
36. HUO D, Si M, Yu K, Fang X, et al
    Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling.
    Oncogene. 2025 Jul 4. doi: 10.1038/s41388-025-03482.
    PubMed     Abstract available
    
    
    April 2025
37. WALKE P, Price JDW, Vizeacoumar FS, Joseph N, et al
    A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.
    Oncogene. 2025 Apr 29. doi: 10.1038/s41388-025-03413.
    PubMed     Abstract available
    
    
    
38. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03407.
    PubMed    
    
    
    
39. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03392.
    PubMed    
    
    
    March 2025
40. HOFSTAD M, Woods A, Parra K, Sychev ZE, et al
    Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer.
    Oncogene. 2025 Mar 21. doi: 10.1038/s41388-025-03343.
    PubMed     Abstract available
    
    
    
41. YIN L, Dai Y, Wang Y, Liu S, et al
    A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
    Oncogene. 2025 Mar 6. doi: 10.1038/s41388-025-03328.
    PubMed     Abstract available
    
    
    
42. SCHMIDT MJ, Naghdloo A, Prabakar RK, Kamal M, et al
    Polyploid cancer cells reveal signatures of chemotherapy resistance.
    Oncogene. 2025;44:439-449.
    PubMed     Abstract available
    
    
    January 2025
43. KAUSHAL JB, Raut P, Halder S, Alsafwani ZW, et al
    Oncogenic potential of truncated-Gli3 via the Gsk3beta/Gli3/AR-V7 axis in castration-resistant prostate cancer.
    Oncogene. 2025 Jan 16. doi: 10.1038/s41388-024-03266.
    PubMed     Abstract available
    
    
    December 2024
44. DUTTA S, Khedmatgozar H, Patel GK, Latour D, et al
    A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.
    Oncogene. 2024 Dec 20. doi: 10.1038/s41388-024-03252.
    PubMed     Abstract available
    
    
    
45. WOYTASH JA, Kumar R, Chaudhary AK, Donnelly C, et al
    Mitochondrial unfolded protein response-dependent beta-catenin signaling promotes neuroendocrine prostate cancer.
    Oncogene. 2024 Dec 17. doi: 10.1038/s41388-024-03261.
    PubMed     Abstract available
    
    
    November 2024
46. HUANG F, Li K, Chen Z, Cui Z, et al
    Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.
    Oncogene. 2024 Nov 29. doi: 10.1038/s41388-024-03239.
    PubMed     Abstract available
    
    
    
47. RODRIGUES SOUSA E, de Brot S, Zoni E, Zeinali S, et al
    CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.
    Oncogene. 2024 Nov 26. doi: 10.1038/s41388-024-03230.
    PubMed     Abstract available
    
    
    
48. LYU C, Vaddi PK, Elshafae S, Pradeep A, et al
    Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.
    Oncogene. 2024 Nov 13. doi: 10.1038/s41388-024-03224.
    PubMed     Abstract available
    
    
    
49. SHARMA S, Pei X, Xing F, Wu SY, et al
    Correction: Regucalcin promotes dormancy of prostate cancer.
    Oncogene. 2024 Nov 11. doi: 10.1038/s41388-024-03216.
    PubMed    
    
    
    
50. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    Correction: AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03190.
    PubMed    
    
    
    
51. OFFENHAUSER C, Dave KA, Beckett KJ, Smith FM, et al
    EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03206.
    PubMed     Abstract available
    
    
    
52. HUANG H, Zhuang X, Yin S, Sun W, et al
    The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.
    Oncogene. 2024 Nov 2. doi: 10.1038/s41388-024-03209.
    PubMed     Abstract available
    
    
    
53. RHEE JW, Adzavon YM, Sun Z
    Stromal androgen signaling governs essential niches in supporting prostate development and tumorigenesis.
    Oncogene. 2024;43:3419-3425.
    PubMed     Abstract available
    
    
    October 2024
54. WANG K, Chen M, Yan S, Han Y, et al
    Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.
    Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03195.
    PubMed     Abstract available
    
    
    
55. LIN G, Tian F, Yu Q, Weng X, et al
    IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.
    Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169.
    PubMed     Abstract available
    
    
    
56. XIONG X, Zhang S, Zhu W, Du J, et al
    Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells.
    Oncogene. 2024 Oct 5. doi: 10.1038/s41388-024-03181.
    PubMed     Abstract available
    
    
    September 2024
57. MU Y, Wallenius A, Zang G, Zhu S, et al
    The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells.
    Oncogene. 2024 Sep 20. doi: 10.1038/s41388-024-03165.
    PubMed     Abstract available
    
    
    
58. SARDAR S, McNair CM, Ravindranath L, Chand SN, et al
    AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Oncogene. 2024 Sep 13. doi: 10.1038/s41388-024-03148.
    PubMed     Abstract available
    
    
    August 2024
59. YU J, Zhang M, Li T, Gao W, et al
    Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-kappaB activation and promotes docetaxel efficacy in prostate cancer.
    Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03132.
    PubMed     Abstract available
    
    
    
60. XIONG S, Li S, Li Z, Song Y, et al
    A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03120.
    PubMed     Abstract available
    
    
    July 2024
61. JIN Z, Wang H, Tang R, Pan B, et al
    GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-beta axis-mediated antitumor immunity.
    Oncogene. 2024 Jul 27. doi: 10.1038/s41388-024-03107.
    PubMed     Abstract available
    
    
    June 2024
62. LIN G, Zhang F, Weng X, Hong Z, et al
    Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models.
    Oncogene. 2024 Jun 17. doi: 10.1038/s41388-024-03073.
    PubMed     Abstract available
    
    
    
63. CHEN B, Xu P, Yang JC, Nip C, et al
    Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
    Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081.
    PubMed     Abstract available
    
    
    
64. FRANCIS JC, Capper A, Rust AG, Ferro K, et al
    Identification of genes that promote PI3K pathway activation and prostate tumour formation.
    Oncogene. 2024;43:1824-1835.
    PubMed     Abstract available
    
    
    May 2024
65. ZHAO J, Shen J, Mao L, Yang T, et al
    Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
    PubMed     Abstract available
    
    
    
66. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
    PubMed     Abstract available
    
    
    
67. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
    Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
    Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
    PubMed     Abstract available
    
    
    April 2024
68. RAWAT C, Heemers HV
    Alternative splicing in prostate cancer progression and therapeutic resistance.
    Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
    PubMed     Abstract available
    
    
    
69. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.
    PubMed    
    
    
    
70. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    PubMed     Abstract available
    
    
    
71. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed     Abstract available
    
    
    March 2024
72. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    PubMed     Abstract available
    
    
    
73. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    PubMed     Abstract available
    
    
    
74. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995.
    PubMed     Abstract available
    
    
    
75. LI J, Hong Z, Zhang J, Zheng S, et al
    Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Oncogene. 2024;43:744-757.
    PubMed     Abstract available
    
    
    January 2024
76. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    PubMed     Abstract available
    
    
    
77. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    PubMed     Abstract available
    
    
    December 2023
78. FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al
    Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925.
    PubMed     Abstract available
    
    
    
79. MILLER KA, Degan S, Wang Y, Cohen J, et al
    Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920.
    PubMed    
    
    
    
80. CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al
    PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914.
    PubMed     Abstract available
    
    
    November 2023
81. EIGENTLER A, Handle F, Schanung S, Degen A, et al
    Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901.
    PubMed     Abstract available
    
    
    
82. CUI H, Wang Y, Zhou T, Qu L, et al
    Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878.
    PubMed     Abstract available
    
    
    October 2023
83. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    PubMed     Abstract available
    
    
    September 2023
84. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
    Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
    Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum